BMO Starts ArQule (ARQL), Pharmasset (VRUS) at Outperform
Tweet Send to a FriendGet Alerts ARQL Hot Sheet
Price: $2.80 +0.72%
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ARQL Now!
An analyst at BMO Capital has initiated coverage on several stocks in the Biotech & Drugs sector this afternoon, both with Outperform ratings: ArQule (Nasdaq: ARQL) and Pharmasset (Nasdaq: VRUS).
The firm set a $10 price target on ArQule shares and a $41 price target on shares of Pharmasset.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm set a $10 price target on ArQule shares and a $41 price target on shares of Pharmasset.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Cowen Starts Triumph Group (TGI) at Neutral
- Barclays Starts Leap Wireless (LEAP) at Underweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
